Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Jul:262:131-137.
doi: 10.1016/j.atherosclerosis.2017.05.014. Epub 2017 May 12.

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study

Affiliations
Multicenter Study

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study

Anandita Agarwala et al. Atherosclerosis. 2017 Jul.

Abstract

Background and aims: Lipoprotein(a) [Lp(a)] is a proatherogenic lipoprotein associated with coronary heart disease, ischemic stroke, and more recently aortic stenosis and heart failure (HF). We examined the association of Lp(a) levels with incident HF hospitalization in the Atherosclerosis Risk in Communities (ARIC) study. We also assessed the relationship between Lp(a) levels and arterial stiffness as a potential mechanism for development of HF.

Methods: Lp(a) was measured in 14,154 ARIC participants without prevalent HF at ARIC visit 1 (1987-1989). The association of Lp(a) quintiles with incident HF hospitalization was assessed using Cox proportional-hazards models. Arterial stiffness parameters were stratified based on Lp(a) quintiles, and p-trend was calculated across ordered groups.

Results: At a median follow-up of 23.4 years, there were 2605 incident HF hospitalizations. Lp(a) levels were directly associated with incident HF hospitalization in models adjusted for age, race, gender, systolic blood pressure, history of hypertension, diabetes, smoking status, body mass index, heart rate, and high-density lipoprotein cholesterol (quintile 5 vs. quintile 1: hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.09-1.41; p-trend across increasing quintiles <0.01), but not after excluding prevalent and incident myocardial infarction cases (HR 1.07, 95% CI 0.91-1.27; p-trend = 0.70). When adjusted for age, gender, and race, Lp(a) quintiles were not significantly associated with arterial stiffness parameters.

Conclusions: Increased Lp(a) levels were associated with increased risk of incident HF hospitalization. After excluding prevalent and incident myocardial infarction, the association was no longer significant. Lp(a) levels were not associated with arterial stiffness parameters.

Keywords: Heart failure; Lipoproteins; Risk factors; Risk prediction.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

A. Agarwala: none

Y. Pokharel: supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL110837.

A. Saeed: none

W. Sun: none

S. S. Virani: none

V. Nambi: provisional patent along with Roche, Baylor College of Medicine, University of North Carolina on use of biomarkers in prediction of heart failure, regional advisory board Sanofi Regeneron, event adjudicator for a study sponsored by Siemens, site PI for study sponsored by Merck

C. Ndumele: none,

E. Shahar: none

G. Heiss: none

E. Boerwinkle: officer, director, trustee, or other fiduciary role for Codified Genomics

S. Konety: none

R. C. Hoogeveen: research grants from Denka Seiken, Ltd., and Roche.

C. M. Ballantyne: consultant fees/honoraria from Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, Ionis, Matinas BioPharma Inc, Merck & Company, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; research/research grants from Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Otsuka, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda; a provisional patent (patent #61721475) entitled ”Biomarkers to Improve Prediction of Heart Failure Risk” was filed by Drs. Ballantyne, Hoogeveen, and Nambi, Baylor College of Medicine and Roche.

Figures

Fig. 1
Fig. 1
Cumulative incidence of heart failure hospitalization by Lp(a) quintiles at ARIC visit 1. Higher Lp(a) quintiles at visit 1 were significantly associated with greater risk for incident heart failure hospitalization in unadjusted models. p values were calculated by log-rank trend tests of survival functions across Lp(a) quintiles.

Similar articles

Cited by

References

    1. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241–249. - PMC - PubMed
    1. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, Rumley A, Lowe GD, Danesh J, Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168:598–608. - PubMed
    1. Johannsen TH, Kamstrup PR, Andersen RV, Jensen GB, Sillesen H, Tybjaerg-Hansen A, Nordestgaard BG. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab. 2009;94:1264–1273. - PubMed
    1. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296:1363–1370. - PubMed
    1. Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns RJ, Boersma E, Van Domburg RT, Serruys PW. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol. 2012;35:482–489. - PMC - PubMed

Publication types

MeSH terms